This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Modernatx, Inc.. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Innovations of Li Ming Gan in RNA Therapeutics
Introduction
Li Ming Gan is a notable inventor based in Mölndal, Sweden. He has made significant contributions to the field of RNA therapeutics, particularly in the development of modified RNA molecules. His work focuses on advancing treatments for diseases that respond to vascular endothelial growth factor A (VEGF-A) therapy.
Latest Patents
Li Ming Gan holds 1 patent for his invention titled "Modified RNA encoding VEGF-A polypeptides, formulations, and uses relating thereto." This patent discloses modified RNA molecules that encode VEGF-A polypeptides and formulations that include these modified RNA molecules. The invention also covers preparations and applications of these formulations in treating subjects suffering from diseases that are responsive to VEGF-A therapy.
Career Highlights
Li Ming Gan is currently associated with Modernatx, Inc., a company that focuses on innovative RNA-based therapies. His work at Modernatx has positioned him as a key player in the development of cutting-edge treatments that leverage the potential of RNA technology.
Collaborations
Li Ming Gan collaborates with several talented individuals in his field, including Leif Karlsson Parinder and Regina Desirée Fritsche Danielson. Their combined expertise contributes to the advancement of research and development in RNA therapeutics.
Conclusion
Li Ming Gan's innovative work in modified RNA therapeutics represents a significant advancement in medical science. His contributions are paving the way for new treatment options for patients in need.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile